



FOR IMMEDIATE RELEASE

caprotec bioanalytics Announces Commercial Launch Of Three New caproKits(TM) For Applications In Proteomics And Drug Development

Berlin, Germany and Burlington, MA, January 26, 2010 – caprotec bioanalytics GmbH announced today the commercial launch of three new caproKits(TM), enabling the discovery, identification and characterization of proteins belonging to the groups of metallo-proteases, histon-deacetylases and GDP/GTP binding proteins.

The three new kits are the Marimastat caproKit, SAHA caproKit and GDP caproKit, respectively and increase the number of commercially available caproKits to a total of seven.

The company's caproKits are based on the proprietary Capture Compound Mass Spectrometry (CCMS) technology, a novel and direct way to investigate small molecule - protein interactions resulting in a significant functional reduction of proteome complexity. Capture Compounds(TM) enable direct isolation and identification of proteins including membrane proteins out of complex biological samples.

The new and existing caproKits target different areas of research ranging from signal transduction (cAMP, cGMP, Stauro and the new GDP caproKit) to epigenetics (SAH and the new SAHA caproKit), and proteases (Marimastat caproKit). Additional caproKits for applications in these and other research areas are under development and will be released in the coming months.

“Our new caproKits are innovative and effective tools for researchers in the field of proteomics needing a solution for targeted reduction of sample complexity,” stated Dr. Hubert Köster, CEO of caprotec bioanalytics. “Our most recent scientific publications in *Molecular and Cellular Proteomics* and *Toxicological Sciences* provide powerful testimonials for the capabilities of our CCMS technology.”

About caprotec bioanalytics GmbH

caprotec bioanalytics is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. The company focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called Capture Compounds(TM). They enable a targeted isolation of proteins directly from complex biological samples. After isolation the captured proteins are identified and characterized by mass spectrometry or gel electrophoresis and Western blotting. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of biomarkers. The technology is protected by a broad patent portfolio.

Publications:

Luo, Y. et al. (2009), *Mol. Cell. Proteomics* 8, pp. 2843-2856: The cAMP capture compound mass spectrometry as a novel tool for targeting cAMP-binding proteins: from protein kinase A to potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channels.

Fischer, J.J. et al. (2009), *Toxicol. Sci., in press*, advanced online publication available: Capture Compound Mass Spectrometry (CCMS) Sheds Light on the Molecular Mechanisms of Liver Toxicity of two Parkinson Drugs.

For further information please contact:

Dr. Hubert Köster, CEO, caprotec GmbH
Phone: +49 (0)30-6392-3990

or

Dr. Christian Jurinke, President, caprotec Inc.
Phone: (781) 685-4992
info@caprotec.com
www.caprotec.com